Innate Pharma CD73 Blocking Antibodies Patent EP3959239A1
Summary
The European Patent Office granted patent EP3959239A1 to Innate Pharma for CD73 blocking antibodies, covering compositions and methods for treating cancer and infectious diseases. The patent names Laurent Gauthier, Carine Paturel, and Ivan Perrot as inventors and designates all EU member states. Patent protection extends for the standard term under EPC provisions.
What changed
The European Patent Office published patent EP3959239A1 for Innate Pharma covering human CD73 blocking antibodies and their therapeutic uses. The patent includes claims to antibody compositions, methods of treatment for cancers (A61P 35/00) and infectious diseases (A61P 31/00), and is classified under C07K 16/28.
Pharmaceutical and biotech companies developing CD73-targeted therapeutics should conduct Freedom to Operate analyses to assess potential infringement risks. Competitors may need to design around the claims or explore licensing options with Innate Pharma. Research institutions and clinical trial sponsors should similarly evaluate this IP position when planning CD73-related development programs.
What to do next
- Review patent claims for CD73 antibody programs
- Assess Freedom to Operate for competing CD73-targeted therapeutics
- Monitor for potential licensing opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CD73 BLOCKING ANTIBODIES
Publication EP3959239A1 Kind: A1 Apr 01, 2026
Applicants
Innate Pharma
Inventors
GAUTHIER, Laurent, PATUREL, Carine, PERROT, Ivan
IPC Classifications
C07K 16/28 20060101AFI20201030BHEP A61P 31/00 20060101ALI20201030BHEP A61P 35/00 20060101ALI20201030BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.